MedTrace Logo

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

NCT04279769 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-04-13

No results posted yet for this study

Summary

This is a phase 1b multiple ascending dose escalation study to evaluate the safety and tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.

Conditions

Interventions

DRUG

CB-280

CB-280, oral capsule administered twice daily at the assigned dose level for 14 days

DRUG

Placebos

Placebo oral capsule administrated twice daily at the assigned dose level for 14 days

Sponsors & Collaborators

  • Calithera Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Emil T Kuriakose, MD · Calithera Bioscience

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-03
Primary Completion
2021-11-23
Completion
2021-11-23
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04279769 on ClinicalTrials.gov